BioSpace News Archive

AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, announced that it has priced an underwritten offering of 14.3 million of its common shares at a price of USD 3.50 per share.

Moderna, Inc. (Nasdaq:MRNA) today announced the publication of positive Phase 3 clinical study results evaluating mRNA-1345, its vaccine candidate for respiratory syncytial virus (RSV), in The New England Journal of Medicine.

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced the initiation of dosing in the Phase 2 FORWARD-53 clinical trial, which is evaluating WVE-N531 as a treatment for boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping.

Halia Therapeutics today announced that the company will present at the 13th World Gastroenterology, IBD & Hepatology Conference taking place during December 15-17, 2023, in Dubai, United Arab Emirates and virtually.

Sanofi announced that its Q4 2023 Memorandum for modelling purposes is available on the “Investors” page of the company’s website.

CymaBay Therapeutics, Inc. (NASDAQ: CBAY) today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for investigational treatment, seladelpar, for the management of primary biliary cholangitis, including pruritus in adults without cirrhosis or with compensated cirrhosis (Child Pugh A) who are inadequate responders or intolerant to ursodeoxycholic acid (UDCA).

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the conditional approval of CASGEVY™ .

Zymeworks Inc., a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, announced it is expected to be added to the Nasdaq Biotechnology Index .

Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent libraries and AI tools, announced that Nassim Usman, Ph.D., has been named President & Chief Executive Officer and closed a $66M Series B financing led by DCVC Bio.

Abbott announced that its board of directors has increased the company’s quarterly common dividend to 55 cents per share, an increase of 7.8%.